Jaszczuk Ilona, Schlotawa Lars, Dierks Thomas, Ohlenbusch Andreas, Koppenhöfer Dominique, Babicz Mariusz, Lejman Monika, Radhakrishnan Karthikeyan, Ługowska Agnieszka
University Children Hospital, Paediatric Haematology, Oncology and Transplantology Department, Lublin, Poland.
Department of Medical Genetics, University of Cambridge, Cambridge Institute for Medical Research, Cambridge CB2 0XY, UK; Department of Physiology, Development and Neuroscience, University of Cambridge, Cambridge CB2 3EG, UK.
Mol Genet Metab. 2017 Jul;121(3):252-258. doi: 10.1016/j.ymgme.2017.05.013. Epub 2017 May 22.
Multiple sulfatase deficiency (MSD) is a rare inherited metabolic disease caused by defective cellular sulfatases. Activity of sulfatases depends on post-translational modification catalyzed by formylglycine-generating enzyme (FGE), encoded by the SUMF1 gene. SUMF1 pathologic variants cause MSD, a syndrome presenting with a complex phenotype. We describe the first Polish patient with MSD caused by a yet undescribed pathologic variant c.337G>A [p.Glu113Lys] (i.e. p.E113K) in heterozygous combination with the known deletion allele c.519+5_519+8del [p.Ala149_Ala173del]. The clinical picture of the patient initially suggested late infantile metachromatic leukodystrophy, with developmental delay followed by regression of visual, hearing and motor abilities as the most apparent clinical symptoms. Transient signs of ichthyosis and minor dysmorphic features guided the laboratory workup towards MSD. Since MSD is a rare disease and there is a variable clinical spectrum, we thoroughly describe the clinical outcome of our patient. The FGE-E113K variant, expressed in cell culture, correctly localized to the endoplasmic reticulum but was retained intracellularly in contrast to the wild type FGE. Analysis of FGE-mediated activation of steroid sulfatase in immortalized MSD cells revealed that FGE-E113K exhibited only approx. 15% of the activity of wild type FGE. Based on the crystal structure we predict that the exchange of glutamate-113 against lysine should induce a strong destabilization of the secondary structure, possibly affecting the folding for correct disulfide bridging between C235-C346 as well as distortion of the active site groove that could affect both the intracellular stability as well as the activity of FGE. Thus, the novel variant of the SUMF1 gene obviously results in functionally impaired FGE protein leading to a severe late infantile type of MSD.
多种硫酸酯酶缺乏症(MSD)是一种由细胞硫酸酯酶缺陷引起的罕见遗传性代谢疾病。硫酸酯酶的活性取决于由SUMF1基因编码的甲酰甘氨酸生成酶(FGE)催化的翻译后修饰。SUMF1基因的病理变异会导致MSD,这是一种具有复杂表型的综合征。我们描述了首例波兰MSD患者,该患者由一个尚未描述的病理变异c.337G>A [p.Glu113Lys](即p.E113K)与已知的缺失等位基因c.519+5_519+8del [p.Ala149_Ala173del]杂合而成。该患者的临床表现最初提示为晚发性婴儿型异染性脑白质营养不良,发育迟缓,随后视觉、听力和运动能力衰退是最明显的临床症状。鱼鳞病的短暂体征和轻微的畸形特征促使实验室检查朝着MSD的方向进行。由于MSD是一种罕见疾病且临床谱存在差异,我们详细描述了该患者的临床结局。在细胞培养中表达的FGE-E113K变异体正确定位于内质网,但与野生型FGE相比,被保留在细胞内。对永生化MSD细胞中FGE介导的类固醇硫酸酯酶激活的分析表明,FGE-E113K仅表现出野生型FGE约15%的活性。基于晶体结构我们预测,将谷氨酸-113替换为赖氨酸会导致二级结构强烈不稳定,可能影响C235-C346之间正确二硫键桥接的折叠以及活性位点凹槽的扭曲,这可能会影响FGE的细胞内稳定性及其活性。因此,SUMF1基因的新型变异显然导致功能受损的FGE蛋白,从而导致严重的晚发性婴儿型MSD。